Eli Lilly Signs an Exclusive Worldwide License Agreement with Centrexion Therapeutics for its CNTX-0290

Shots:

• Centrexion to receive $47.5M upfront, up to $950M as development, regulatory & commercial milestones and royalties on sales of product. Lilly to get exclusive WW rights for CNTX-0290 & will co-promote CNTX-0290 with Centrexion in the US
• The focus of the collaboration is to strengthen Lilly’s pain management portfolio and allow Centrexion to focus on new targets for chronic pain
• Centrexion’s CNTX-0290 is a somatostatin receptor type 4 (SSTR4) agonist, is being evaluated in P-I as a non-opioid treatment for chronic pain

Click here to read full press release/ article | Ref: Eli Lilly | Image: Pinterest